Details of the Drug

General Information of Drug (ID: DM0QH9K)

Drug Name
FS118
Indication
Disease Entry ICD 11 Status REF
Advanced cancer 2A00-2F9Z Phase 1 [1]
Advanced malignancy 2A00-2F9Z Phase 1 [2]
Drug Type
Antibody
Cross-matching ID
TTD ID
D0XO9F

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Lymphocyte activation gene 3 protein (LAG3) TTNVXAW LAG3_HUMAN Not Available [1]
Programmed cell death 1 ligand 1 (PD-L1) TT8ZLTI PD1L1_HUMAN Not Available [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Advanced cancer
ICD Disease Classification 2A00-2F9Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Programmed cell death 1 ligand 1 (PD-L1) DTT CD274 4.38E-07 0.37 2.1
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)